Plenary Session

Latest Episodes:

2.25 Questions of the Week: Hematology/Oncology, the USMLE Step 2 CK, & One From a Med Student Dec 02, 2019

Show notes

Our host is still out of town, but don't worry -- we have some questions of the week to tide you over. The first is inspired by the hematology/oncology boards, presented by Dr. Sven Olson; the second is inspired by the USMLE Step 2 CK, presented by Ian Straehley; and the third is from Audrey Tran, inspired by her experiences as a med student. Back us on Patreon! www.patreon.com/plenarysession

2.24 Questions of the Week: the USMLE Step 2 CK, Hematology/Oncology, & One From a Med Student Nov 26, 2019

Show notes

This week our host is still in Australia, but we have some questions of the week saved for you! The first is inspired by the USMLE Step 2 CK, presented by Ian Straehley; the second is inspired by the hematology/oncology boards, presented by Dr. Sven Olson; and the third is from Audrey Tran, inspired by her experiences as a med student. Back us on Patreon! www.patreon.com/plenarysession

2.23 Question of the Week & Ethics and Inefficiencies of Clinical Trials with Dr. Jonathan Kimmelman Nov 20, 2019

Show notes

First up this week is Question of the Week inspired by the Hematology/Oncology boards, with Dr. Sven Olson. No monologue on current trials this week because our host is still in Australia, so we conclude the episode with an interview with Dr. Jonathan Kimmelman of McGill University on his extensive work in research ethics, studying the most important issue in cancer medicine today: the risk-benefit of clinical trials and how best to spare patients from the burdens of creating a new drug. Review of Sunitinib: doi.org/10.1093/jnci/djv292 Benefit, Burden, and Impact: doi.org/10.1177/1740774519873883 Back us on Patreon! www.patreon.com/plenarysession

2.22 Question of the Week & EMR, Talking to Patients, and Being a Doctor with Dr. Robert Hirschtick Nov 15, 2019

Show notes

This week we have a question of the week from Ian Straehley, inspired by the USMLE Step 2 CK, as well as an interview with Dr. Robert Hirschtick of Northwestern University on what it means to be a doctor, how you should think as a physician, and his many popular pieces published in journals like JAMA. "Copy-and-Paste": doi.org/10.1001/jama.295.20.2335 "Extremities": doi.org/10.1001/jama.300.10.1125 "The Quick Physical Exam": doi.org/10.1001/jama.2016.8182 Robiewon on YouTube: www.youtube.com/channel/UC2Ki7Zbo2VCGQAYinsJhU3w "You Did Not Teach Me What You Thought You Did": doi.org/10.1001/jama.2019.15849 Back us on Patreon! www.patreon.com/plenarysession

2.21 Aiming for the Hard Targets & Harm From Screening and Overdiagnosis with Dr. H Gilbert Welch Nov 08, 2019

Show notes

We begin this week's episode by addressing a listener's feedback to our discussion of smoldering multiple myeloma. We then expand on our critique of 'going after the soft targets' (criticizing studies that fall apart with little resistance) by elucidating how to identify and go after hard targets and why it's so important that you do. Finally, we launch into an interview with Dr. H Gilbert Welch that explores his tremendous body of work on the preventable harm that comes from too generous a hand with novel diagnostic advances. Back us on Patreon! www.patreon.com/plenarysession

2.20 "Courageous Skeptics", Lenalidomide, QOTW, and a Political Conversation with Dr. Andy Saultz Nov 01, 2019

Show notes

We begin this week's episode with a thoughtful discussion of the internet's "courageous skeptics". Then, after lamenting the way in which the recent study "Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma" was conducted, we end with an interview with Dr. Andy Saultz on his ongoing campaign for Oregon state representative. We break up the interview with a couple Hem/Onc boards questions of the week from Dr. Emerson Chen. Lenalidomide in Smoldering Multiple Myeloma: doi.org/10.1200/JCO.19.01740 Back us on Patreon! www.patreon.com/plenarysession

2.19 Remembering Dr. Bernard Fisher & Self-Diagnosis with Dr. Mark Lewis Oct 25, 2019

Show notes

This week we give a short monologue on the late Dr. Bernard Fisher's legacy in the field of oncology, and then dive into a far-ranging interview with Dr. Mark Lewis of Intermountain Healthcare on his career, his family, and diagnosing himself with MEN1 syndrome. Dr. Fisher's obituary in the New York Times: https://www.nytimes.com/2019/10/19/science/dr-bernard-fisher-dead.html Back us on Patreon! www.patreon.com/plenarysession

2.18 Questions of the Week, Talking About Toxicity, ASCO Guidelines Authors' COI with Dr. Eitan Amir Oct 18, 2019

Show notes

This week we begin with a critique of the recent perspective article in the New England Journal of Medicine, titled "Talking about Toxicity — 'What We’ve Got Here Is a Failure to Communicate'". After that we interview Dr. Eitan Amir on his paper on undisclosed conflicts of interest among authors of ASCO guidelines. Interspersed between segments of the interview, we invite guest Dr. Sven Olson on to offer a correction to a recent Hem/Onc boards question of the week on Lynch Syndrome (original question posed in episode 2.11) and we invite Ian Straehley on for a question of the week inspired by the USMLE Step 2 CK. Talking about toxicity: doi.org/10.1056/NEJMp1908310 COI among authors of ASCO guidelines: doi.org/10.1002/cncr.32408 Transparency in medicine: doi.org/10.1002/cncr.32407 Back us on Patreon! www.patreon.com/plenarysession

2.17 Questions of the Week, BEACON, & Use of Subacuate Rehab with Dr. Jonathan Yeh Oct 08, 2019

Show notes

We start this week's episode with a quick breakdown of why the recent BEACON trial is "the worst trial" host VP has ever read. After that, we have two questions of the week: one from medical student Audrey Tran, and one inspired by the Hem/Onc boards from Dr. Sven Olson. We end with an interview with Dr. Jonathan Yeh of Johns Hopkins University School of Medicine on his recent paper: "Has There Been a Shift in Use of Subacute Rehabilitation Instead of Hospice Referral Since Immunotherapy Has Become Available?". BEACON: doi.org/10.1056/NEJMoa1908075 Subacute Rehabilitation: doi.org/10.1200/JOP.19.00044 Back us on Patreon! www.patreon.com/plenarysession

2.16 FLAURA & What Truly Matters in the Career of an Academic Physician with Dr. Vinay Prasad Oct 02, 2019

Show notes

This week we break down the limitations of the recent FLAURA trial and then we're back in the Plenary Session Mobile Command Unit! We have a special guest host, Dr. Christopher Booth of Queen's University in Kingston, Ontario, Canada. He and Dr. Bishal Gyawali, also of Queen's University, conduct a reverse interview with our usual host, Dr. Vinay Prasad of Oregon Health & Science University, on his career, the formation of Plenary Session, and what truly matters in the career of an academic physician. FLAURA: doi.org/10.1056/NEJMoa1713137 Price of an Anticancer Drug: doi.org/10.1001/jamainternmed.2017.3601 Simply Measurable or Clinically Meaningful? doi.org/10.1200/jco.2011.38.7571 The Emperor Has No Clothes: doi.org/10.1200/JCO.2008.19.5594 Making Room in Oncology: www.medscape.com/viewarticle/917628 Back us on Patreon! www.patreon.com/plenarysession

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected